Is Cencora, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is at a risky valuation with a P/E of 57.25.
Cencora's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%. This strong performance reinforces the notion that the stock is fairly valued in the current market environment.